Fertility and Sterility
Volume 90, Issue 3 , Pages 727-730 , September 2008

Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study

  • Jaleh Zolghadri, M.D.

      Affiliations

    • Department of OB & GYN, Shiraz Medical University, Shiraz, Iran
    • Corresponding Author InformationReprint requests: Jaleh Zolghadri, M.D., Department of OB-GYN, Faghihi Hospital, Zand Street, Shiraz, Iran (FAX: 98-711-2332365).
    • ,
  • Zohreh Tavana, M.D.

      Affiliations

    • Department of OB & GYN, Shiraz Medical University, Shiraz, Iran
    • ,
  • Talie Kazerooni, M.D.

      Affiliations

    • Department of OB & GYN, Shiraz Medical University, Shiraz, Iran
    • ,
  • Mahmoud Soveid, M.D.

      Affiliations

    • Department of Medicine, Shiraz Medical University, Shiraz, Iran
    • ,
  • Marzieh Taghieh, M.D.

      Affiliations

    • Department of OB & GYN, Shiraz Medical University, Shiraz, Iran

Received 25 November 2006 ,Revised 23 June 2007 ,Accepted 25 June 2007.

References 

  1. Prport CP, Murphy AA. Endocrinopathies associated with recurrent pregnancy loss. Semin Reprod Med. 2000;18:357–362
  2. Fedele L, Bianchi S. Habitual abortion: endocrinological aspects. Curr Opin Obstet Gynecol. 1995;7:351–356
  3. Saad FA, Jauniaux E. Recurrent early pregnancy loss and consanguinity. Rep Biomed Online. 2002;5:167–170
  4. Crane JP, Wahl N. The role of maternal diabetes in repetitive spontaneous abortion. Fertil Steril. 1981;36:477–479
  5. Coulam CB, Stern JJ. Endocrine factors associated with recurrent spontaneous abortion. Clin Obstet Gynecol. 1994;37:730–734
  6. Carrington B, Sacks G, Regan L. Recurrent miscarriage pathophysiology and outcome. Curr Opin Obstet Gynecol. 2005;17:591–597
  7. Catrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol. 2005;17:591–597
  8. Latasha B, Craig MO, Raymond W, Williams MH, Katten . Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril. 2002;78:487–489
  9. Sutherland HW, Fisher PM. Fetal loss and maternal glucose intolerance. A retrospective study. Padia-pradol. 1982;17:279–286
  10. Yong EH, Sun NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profile in women with clomiphene-resistant polycystic ovaries: a randomized double-blinded placebo-controlled trial. Hum Reprod. 2001;16:1625–1631
  11. Glueck CJ, Sherif G, Awadella MO, Harvey PH. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos and miscarriage. Fertil Steril. 2000;74:394–397
  12. Regan L, Owen EJ, Jacob HS. Hypersecretion of luteinizing hormone infertility and miscarriage. Lancet. 1990;336:1141–1144
  13. Glueck CJ, Harvey PH. Dancameron. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first trimester spontaneous abortion, a pilot study. Fertil Steril. 2001;75:46–52
  14. Glueck CJ, Wang P, Goldenberg N, Smith LS. Pregnancy outcome among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17:2858–2864
  15. Jakubowicz DJ, Iuorno MJ, Salmon J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clinic Endocrinol. 2002;87:524–529
  16. Palomba S, Falbo A, Otio F, Russo T, Tolino A, Zullo F. Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. Fertil Steril. 2006;85:1511
  17. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis enoxaparin, metformin. Clin Appl Thromb Hemost. 2004;10:323–334
  18. Jakubowicz DJ, Seppalam , Jakubowicz S. Metformin increases luteal phase, serum glycodelin and insulin-like growth factor-binding protein-1 concentrations and enhances uterine vascularity and enhances uterine blood follow in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1126–1133
  19. Atiomo WU, Bates SA, Condon JE, Shaw S, West JN, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril. 1998;69:236–241
  20. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profile and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol. 1996;45:623–629
  21. Glueck CJ, Wang P, Fontine RN, Sieve L, Smith LS. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48:1589–1595
  22. Gris JC, Neveo S, Maru P, Biron C, Medon B, Schred JF. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med. 1993;122:606–615

PII: S0015-0282(07)01433-1

doi: 10.1016/j.fertnstert.2007.06.079

Fertility and Sterility
Volume 90, Issue 3 , Pages 727-730 , September 2008

Article Tools